Neuronal regeneration after injury: a new perspective on gene therapy

Zeng, Chih-Wei; Zhang, Chunli

doi:10.3389/fnins.2023.1181816

Cited by 10 publications

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Promising therapeutic approaches that are currently in development broadly target the protection of nervous system tissue from further damage or promote axon regeneration, plasticity, and repair, to either lessen functional loss or restore function, respectively. These approaches include (1) pharmacological therapies that target the processes of inflammation, cell death, gliosis, or abortive axon growth [3][4][5][6]; (2) transplantation of cells into the injured cord to replace lost tissue or act as a bridge for regeneration [7][8][9][10][11], including Schwann cells [12][13][14][15], olfactory ensheathing cells [16][17][18], mesenchymal stem cells [19,20], or induced pluripotent stem cells [21][22][23][24]; (3) gene therapy with viral-vector-mediated delivery of genes encoding factors that are neurotrophic or neuroprotective [25][26][27][28][29]; (4) biomaterials and synthetic scaffolds of polymers and gels that can bridge the gap between injured axons and their targets or which possess the capacity to deliver growth promoting molecules [30][31][32][33][34][35];…”

Section: Spinal Cord Injury and Promising Therapeutic Approaches For ...mentioning

confidence: 99%

Schwann Cell-Derived Exosomal Vesicles: A Promising Therapy for the Injured Spinal Cord

Ghosh,

Pearse

2023

IJMS

View full text Add to dashboard Cite

Exosomes are nanoscale-sized membrane vesicles released by cells into their extracellular milieu. Within these nanovesicles reside a multitude of bioactive molecules, which orchestrate essential biological processes, including cell differentiation, proliferation, and survival, in the recipient cells. These bioactive properties of exosomes render them a promising choice for therapeutic use in the realm of tissue regeneration and repair. Exosomes possess notable positive attributes, including a high bioavailability, inherent safety, and stability, as well as the capacity to be functionalized so that drugs or biological agents can be encapsulated within them or to have their surface modified with ligands and receptors to imbue them with selective cell or tissue targeting. Remarkably, their small size and capacity for receptor-mediated transcytosis enable exosomes to cross the blood–brain barrier (BBB) and access the central nervous system (CNS). Unlike cell-based therapies, exosomes present fewer ethical constraints in their collection and direct use as a therapeutic approach in the human body. These advantageous qualities underscore the vast potential of exosomes as a treatment option for neurological injuries and diseases, setting them apart from other cell-based biological agents. Considering the therapeutic potential of exosomes, the current review seeks to specifically examine an area of investigation that encompasses the development of Schwann cell (SC)-derived exosomal vesicles (SCEVs) as an approach to spinal cord injury (SCI) protection and repair. SCs, the myelinating glia of the peripheral nervous system, have a long history of demonstrated benefit in repair of the injured spinal cord and peripheral nerves when transplanted, including their recent advancement to clinical investigations for feasibility and safety in humans. This review delves into the potential of utilizing SCEVs as a therapy for SCI, explores promising engineering strategies to customize SCEVs for specific actions, and examines how SCEVs may offer unique clinical advantages over SC transplantation for repair of the injured spinal cord.

show abstract

Section: Spinal Cord Injury and Promising Therapeutic Approaches For ...mentioning

confidence: 99%

Schwann Cell-Derived Exosomal Vesicles: A Promising Therapy for the Injured Spinal Cord

Ghosh,

Pearse

2023

IJMS

View full text Add to dashboard Cite

show abstract

Applications and Developments of Gene Therapy Drug Delivery Systems for Neurological Disorders

Nguyen,

Nguyen‐Thi,

Nguyen

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

Neurological diseases (NDs) such as Alzheimer's disease, Parkinson's disease, ischemic strokes, spinal cord injuries, and other similar conditions that continue to pose a substantial health and economic burden on a global scale. It is crucial to tackle the difficulties provided by current medications due to the adverse effects and its immunological reactions to develop improved treatments for neurodegenerative illnesses. Gene therapy is currently being extensively used in preclinical and clinical studies for various diseases because of its ability to enhance the delivery and effectiveness of treatments. Various gene delivery techniques, including messenger RNA, small interfering RNA, antisense oligonucleotides, microRNA, CRISPR/Cas9 system, and plasmid DNA, have been created to address these difficulties. The goal of this study is to provide a clear overview of the pathophysiological underpinnings of NDs illnesses while also illuminating recent developments in gene delivery vector technologies. It goes over the main classifications of these vectors, their individual benefits and drawbacks, and their specific applications in the delivery of gene therapy.

show abstract